Perry Mayo-Malasky's questions to Lyra Therapeutics (LYRA) leadership • Q1 2021
Question
Perry Mayo-Malasky of BTIG inquired about the preferred time point for the upcoming Phase 3 trial, given the efficacy seen at 24 weeks in the LANTERN study, and also asked about the progress of manufacturing capabilities for both the Phase 3 trial and future commercialization.
Answer
President and CEO Maria Palasis confirmed that a later time point, up to 24 weeks, would be proposed for the Phase 3 trial due to strong statistical significance (p=0.003 for three cardinal symptoms). She also stated that the technology transfer to their contract manufacturer is progressing well, emphasizing the partner's strength in automation which will be crucial for scaling up to meet the needs of millions of CRS patients upon commercialization.